Inside Syntekabio’s STB CLOUD
The World of Drug Discovery: Time, Cost, and Uncertainty
Drug discovery has always faced the barriers of time, cost, and uncertainty.
Finding, optimizing, and evaluating drug candidates requires countless trials and enormous resources.
Recently, however, an innovative shift has begun to change how these challenges are addressed.
In 2022, Syntekabio officially launched “STB CLOUD”, the world’s first fully automated,
cloud-based AI drug discovery platform, in both Korea and the United States.
This platform standardizes, automates, and simplifies the traditionally complex
and daunting drug discovery process—allowing users to obtain drug candidate results with just a few clicks.
BIO Meets IT: STB CLOUD
AI-driven drug discovery requires massive amounts of data and the infrastructure to handle it, such as:
3D protein structure data
Compound libraries numbering in the hundreds of millions
Dynamic motion data describing protein–compound interactions
To process such data, researchers typically need supercomputing environments,
petabyte-scale storage, hundreds of bioinformatics software tools, and complex workflow scripts.
Even for experienced experts, these tasks are extremely difficult to manage.
STB CLOUD breaks through these barriers.
By integrating heterogeneous hardware (CPU, GPU, etc.), hundreds of bioinformatics software tools,
and modern IT automation technologies like Kubernetes and Docker, Syntekabio has achieved a true convergence of BIO and IT.
The result: complex data and software can now function together as a single solution platform.
DeepMatcher® and the One-Click Service
The first flagship service of STB CLOUD is DeepMatcher®, which executes the following steps:
Virtual Screening – Hundreds of GPUs and CPUs simultaneously explore 1 billion compounds per target protein
Deep Screening – Generate optimal protein–ligand binding structures
Molecular Dynamics Verification – Hundreds of GPUs run for a week to evaluate final validity
All of these processes run automatically through hundreds of scripts—without direct researcher intervention.
Users only need to select a target protein and click. Within three weeks,
they receive an AI-Hit Report containing promising hit candidates, which are then further optimized into AI-Lead compounds.
What once required supercomputers and experts can now be done on an ordinary computer
—even from a café with just a network connection.
How STB CLOUD Differs from SaaS
Many AI drug discovery platforms are offered as SaaS (Software as a Service),
where researchers must operate software, process data, and generate results themselves.
This still demands specialized expertise and access to infrastructure.
In contrast, STB CLOUD is a total service.
It does not merely provide software—it delivers the actual drug candidate results.
No hardware, no software installation, no deep expertise required—only an internet connection.
As a cloud-based, fully automated system, STB CLOUD represents an evolution beyond traditional SaaS.
Upcoming AI Platforms on STB CLOUD
STB CLOUD is continuously expanding beyond DeepMatcher® with additional AI-driven platforms:
NEO-ARS™ – Neoantigen discovery platform predicting tumor-specific peptide variants from cancer patient samples
Auto-Lead-Opt – Automated lead optimization platform
Tox/ADME – Platform predicting drug toxicity and metabolism profiles
AI Antibody Drug Platform – Antibody drug discovery using AI
PGM-ARS, NGS-ARS – Genomic platforms supporting precision medicine and biomarker discovery
With these integrated into the cloud,
researchers will be able to advance drug discovery faster, more efficiently, and without geographical limitations.
What STB CLOUD Represents
Traditionally, drug discovery was seen as the domain of large pharmaceutical companies,
requiring immense capital, infrastructure, and manpower.
STB CLOUD breaks down these barriers by providing:
Time savings – From months to weeks for candidate discovery
Cost reduction – No need for supercomputing infrastructure or large expert teams
Accessibility – Anyone, anywhere, with just a few clicks
Even biotech companies with limited resources can now expand their pipelines quickly
and reduce R&D uncertainty through STB CLOUD.
✅ In Summary
STB CLOUD is the product of true BIO–IT convergence.
It is a cloud-based, fully automated drug discovery platform that goes beyond SaaS
—delivering AI-Hit → AI-Lead results in weeks, from anywhere in the world.
With upcoming AI platforms to cover the entire drug discovery cycle,
STB CLOUD will evolve into a comprehensive enabler of next-generation drug development.
Drug discovery is no longer reserved for big pharma.
With STB CLOUD, Syntekabio is opening new possibilities for researchers and companies worldwide
—and is placing itself at the center of this transformation.
🔗 Open Link
[Feature] Syntekabio Draws the Future of “AI Drug Discovery Pipeline & Drug Repurposing” <2>
